Ulcerative colitis (acute exacerbations) - infliximab (TA163)
Fast, easy summary view of NICE guidance on 'ulcerative colitis'
Infliximab is recommended as a possible treatment for people with acute, severely active ulcerative colitis only if:
- ciclosporin is considered inappropriate for them, or
- they are taking part in a research study (clinical trial)
This guidance has been incorporated into the following NICE Pathways, along with other related guidance and products.
Visit the NICE Pathway: ulcerative colitis
This page was last updated: 25 June 2013
Information for the public
Implementation tools and resources
- Audit support
- Costing report
- Biologic drugs for the treatment of inflammatory disease in rheumatology, dermatology and gastroenterology commissioning guide
See this guidance in practice
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.